Fig 1.
Flowchart of patients included in the study for the untreated and the treated group.
Table 1.
Clinical characteristics of patients in the treated and the untreated group.
Fig 2.
Boxplots of distributions of percentage of positive cells for (A) the untreated group and (B) the treated group. Wilcoxon signed-rank test P values are included comparing biopsy 1 and 2 in the untreated group, and primary and relapse biopsies in the treated group.
Fig 3.
Representative PD-1 and PD-L1/PAX5 immunohistochemical stainings at 400x magnification with untreated (A-D) and treated (E-H) patients. Brown membranous staining indicates PD-1+ or PD-L1+ cells, while red nuclear staining indicates PAX5+ cells. Untreated: (A) Case 9 biopsy 1 (average 4% PD-1+ leukocytes), (B) case 9 biopsy 2 (average 7% PD-1+ leukocytes), (C) case 11 biopsy 1 (average 5% PD-L1+ leukocytes and 0% PD-L1+ HRS cells), and (D) case 11 biopsy 2 (average 10% PD-L1+ leukocytes and 100% PD-L1+ HRS cells). Treated: (E) Case 29 primary biopsy (average 1% PD-1+ leukocytes), (F) case 29 relapse biopsy (average 16% PD-1+ leukocytes), (G) case 28 primary biopsy (average 10% PD-L1+ leukocytes and 0% PD-L1+ HRS cells), and (H) case 28 relapse biopsy (average 19% PD-L1+ leukocytes and 100% PD-L1+ HRS cells).
Table 2.
Clinicopathological characteristics and proportion of PD-1+ leukocytes, PD-L1+ leukocytes and PD-L1+ HRS cells in the untreated group.
Table 3.
Clinicopathological characteristics and proportion of PD-1+ leukocytes, PD-L1+ leukocytes and PD-L1+ HRS cells in the treated group*.
Fig 4.
Visual summary of the main findings in the study.